Gibson, Dunn & Crutcher LLP advised 89bio, Inc. on its upsized public offering. 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and...
89bio Inc.’s $172 Million Upsized Public Offering
Apogee Therapeutics’ Initial Public Offering
Gibson, Dunn & Crutcher LLP is advising Apogee Therapeutics, Inc. in the offering. Apogee Therapeutics, Inc. (Nasdaq: APGE) announced the pricing of its upsized initial public offering...